Tuesday, October 25, 2005—Among the nearly two dozen hepatitis C meds in the pharma pipeline, three frontrunnersare showing early promise in fighting the liver-attacking virus thatplagues one out of three HIVers—and is famously hard to treat. Reports are due next month from aclinical trial combining one of the three, Idenix Pharmaceuticals’ Valopicitabine, with pegylated interferon.